*
2020 International Biomedical Forum
At Shenzhen Orange Island Shangri-La Resort Hotel On December 4, 2020
Co-Organizers:
1. Shenzhen Huaya Regional Economic Development Service Center
2. International Association of Biomedical Sciences (IABS)
3. Guangzhou Institute of Respiratory Health
Speech:
The Several Latest Progress in the Medical Field in 2020
Yongtian (Brandon) Li President of the IABS Board
Ladies and gentlemen! On behalf of the International Association of Biomedical Sciences, I congratulate the successful convening of the 2020 International Biomedical Forum!
Today, I will introduce the Several Latest Developments in the Medical Field in 2020. First, let’s talk about the development prospects of internet virtual healthcare.
In the summer and fall of 2020, the American online virtual healthcare company Teladoc invested $18.5 billion to acquire a chronic disease management company, Livongo. Just on September 16th, the two companies submitted the final power of attorney, and it is expected to complete the transaction by the end of 2020. Internet virtual healthcare is very convenient for patients. Teladoc patients say, “I can talk to doctors anytime, anywhere, whether I’m at home, in the office, or even driving with my children. Teladoc has been of great help to me.” At the same time, Teladoc’s survey found that after seeing a doctor online, 92% of patients said their problems were solved, proving the effectiveness and applicability of online virtual healthcare.
Therefore, we can see the development prospects of internet virtual healthcare. It not only solves the problem of difficulty in seeing a doctor but also allows many patients to see doctors at home or abroad without leaving their homes. In fact, some patients do not need to go to the hospital or can reduce the number of hospital visits.
Internet virtual healthcare can also free up time for large hospitals to solve more advanced medical problems. If anyone wishes to intervene in this field, the International Association of Biomedical Science (IABS) can provide medical resources from multiple countries. Please contact the IABS if needed at www.ia-bs.org.
Next, let me introduce another area of progress, which is the “Major Breakthrough in Treating Type 1 Diabetes”.
There are 1.25 million people in the United States suffering from type 1 diabetes, requiring lifelong daily insulin injections and blood glucose monitoring. Scientists have long known that the best method is to transplant healthy pancreatic islet cells, but it has been difficult for transplanted β cells to survive. Scientists at the University of Pennsylvania spent 15 years tackling this problem, and just this September, Professor Ming published an article reporting the solution to the long-standing problem of β cell survival after transplantation, which is the invention of the IVM survival environment for islet cells.
Dr. Ming Yu from University of Pennsylvania has published a scientific paper recently that shows the two sets of tissue slices shown in the PowerPoint (PPT) presentation illustrate the difference between transplantation with and without the IVM environment. In the top-left tissue slice, numerous transplanted β cells can be seen in deep blue color, while in the top-right tissue slice, there are no surviving β cells in the transplantation without the IVM environment. The bottom-left image shows the presence of a large amount of insulin (red part), while in the bottom-right image, insulin is hardly visible in the transplantation without using IVM.
Looking at the blood glucose change curve after pancreatic islet cell transplantation, the curve above is the control group without β cell transplantation, and the blood sugar does not decrease. The curve below is the group with β cell transplantation. After transplantation, blood sugar decreased from 450mg to 300mg after 3 hours, and it decreased and maintained around a normal level of 100mg after 6 hours. Patients no longer need insulin injections, proving the success of pancreatic islet cell transplantation.
Finally, let me introduce a “Major Discovery in Preventing and Treating Alzheimer’s Disease” which is commonly known as senile dementia. Although major pharmaceutical companies worldwide have been developing drugs targeting the removal of β-amyloid plaques, they have all ended in failure. In July of this year, Professor Jing Liang from the University of Southern California published an article indicating that mitochondrial damage caused by synthetic scaffold proteins (bridging proteins) leads to the occurrence of Alzheimer’s disease, as it cannot produce ATP. She proposed a new theory, the “Scaffold Protein (Bridging Protein) – Inhibitory Neurological Pathway”, which suggests that the deposition of β-amyloid plaques in the brain is the result of the disease, rather than the cause as previously thought. Through systematic experimental research, it has been proven that intervention with SMT can repair damaged mitochondria, restore the “Scaffold Protein (Bridging Protein) – Inhibitory Neurological Pathway”, control the disease, and rebuild the cognition of Alzheimer’s disease patients. Thank you all! Feel free to ask questions, and you can contact us at any time.